| Biomarker ID | 1152 |
| PMID | 23824564 |
| Year | 2013 |
| Biomarker | Adenosine 50 -diphosphate (ADP); Citrate; Palmitoyl-sphingomyelin; |
| Biomarker Basis | Concentration Based |
| Biomolecule | Metabolites |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Decreased with Upgraded Gleason Score |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Gleason Score Upgrading [6 to 7 (3+4) to 7(4+3) to 8] |
| Type of Biomarker | Prognostic |
| Cohort | 260 patients with Prostate cancer such that Gleason Score 6 = 120; 7 (3+4) = 95; 7 (4+3) = 28; and Gleason Score ≥ 8 = 17 were chosen |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.05 |
| Method Used | gas chromatography-mass spectrometry (GC–MS) |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | NA |